复方减肥药物--Qsymia  

A new oral Weight-loss drug——Qsymia

作　　者：肖典[1] 周辛波[1] 

机构地区：[1]国家应急防控药物工程技术研究中心,军事医学科学院毒物药物研究所,北京100850

出　　处：《临床药物治疗杂志》2016年第1期76-80,共5页Clinical Medication Journal

摘　　要：Qsymia是由美国Vivus公司开发的新型复方减肥药,2012年7月17日,美国FDA批准其作为节食和锻炼疗法的辅助治疗药,适用对象为体质指数(BMI)为30及以上或27及以上且患有与体重相关的疾病(如高血压、高血胆固醇、2型糖尿病等)的成人肥胖者。Qsymia是迄今为止效果最好的减肥药,平均能降低受试者10%的体重,减肥效果是目前市场上其他药物的2倍。Vivus公司已申请Qsymia在中国开展临床试验,其后续进展值得关注。笔者就Qsymia的研发历程、基本性质、作用机制、药动学、药效学、临床试验及应用等研发动态作一概述,以期能为医院临床用药起到指导作用。Qsymia capsule is a combination oral weight-loss pill developed by Vivus company. On July 17 th, 2012, it was approved by FDA as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in overweight or obese adults. Qsymia, which can help patients lose 10% of the baseline body weight, which has the best weight reducing effect among the slimming pills. In addition, Vivus company has filed an application for clinical trials in China and the clinical effect is worth anticipating. The properties, mechanism, pharmacokinetics, pharmacodynamics, clinical trials and applications of Qsymia was reviewed in this article, so as to guide clinical medication for hospital.

关 键 词：Qsymia 芬特明 托吡酯 肥胖 超重 

分 类 号：R979.9[医药卫生—药品]